Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncology practice in the COVID-19 pandemic: a report of a Nigerian expert panel discussion (oncology care in Nigeria during the COVID-19 pandemic).
Olabumuyi AA, Ali-Gombe M, Biyi-Olutunde OA, Gbolahan O, Iwuji CO, Joseph AO, Lasebikan NN, Ogunnorin BO, Omikunle AE, Salako O, Salawu A. Olabumuyi AA, et al. Among authors: salawu a. Pan Afr Med J. 2020 Jul 6;36:153. doi: 10.11604/pamj.2020.36.153.23662. eCollection 2020. Pan Afr Med J. 2020. PMID: 32874417 Free PMC article.
Structures, processes and outcomes between first referral and referral hospitals in low-income and middle-income countries: a secondary preplanned analysis of the FALCON and ChEETAh randomised trials.
NIHR Global Health Research Unit on Global Surgery; Kamarajah SK, Alexander P. NIHR Global Health Research Unit on Global Surgery, et al. BMJ Glob Health. 2024 Nov 7;9(Suppl 4):e015599. doi: 10.1136/bmjgh-2024-015599. BMJ Glob Health. 2024. PMID: 39510564 Free PMC article. Clinical Trial.
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease.
Giani C, Salawu A, Ljevar S, Denu RA, Napolitano A, Palmerini E, Connolly EA, Ogura K, Wong DD, Scanferla R, Rosenbaum E, Bajpai J, Li ZC, Bae S, D'Ambrosio L, Bialick S, Wagner AJ, Lee ATJ, Koseła-Paterczyk H, Baldi GG, Brunello A, Lee YC, Loong HH, Boikos S, Campos F, Cicala CM, Maki RG, Hindi N, Figura C, Almohsen SS, Patel S, Jones RL, Ibrahim T, Karim R, Kawai A, Carey-Smith R, Boyle R, Taverna SM, Lazar AJ, Demicco EG, Bovee JVMG, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Gronchi A, Stacchiotti S. Giani C, et al. Among authors: salawu a. Am J Surg Pathol. 2025 Jan 1;49(1):27-34. doi: 10.1097/PAS.0000000000002330. Epub 2024 Oct 28. Am J Surg Pathol. 2025. PMID: 39466087 Free PMC article.
Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.
Beecroft JR, Brar S, Feng X, Hamilton T, Han-Lee C, Henning JW, Josephy PD, Khalili K, Ko YJ, Lemieux C, Liu DM, MacDonald DB, Noujaim J, Pollett A, Salawu A, Saleh R, Smrke A, Warren BE, Zbuk K, Razak AA. Beecroft JR, et al. Among authors: salawu a. Ther Adv Med Oncol. 2024 Aug 2;16:17588359241266179. doi: 10.1177/17588359241266179. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39386314 Free PMC article. Review.
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.
Giani C, Denu RA, Ljevar S, Gronchi A, Napolitano A, Rosenbaum E, Salawu A, Bajpai J, Connolly EA, Lee ATJ, Trent JC, Koseła-Paterczyk H, Chia-Chen Li Z, Ogura K, Palmerini E, Baldi GG, Brunello A, Campos F, Cicala CM, Maki RG, Wagner AJ, Andelkovic V, Loong HH, Wong DD, Jones RL, Tap WD, Taverna SM, Lazar AJ, Demicco EG, Hong A, Bovee JVMG, Dei Tos AP, Fletcher CDM, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Stacchiotti S. Giani C, et al. Among authors: salawu a. ESMO Open. 2024 Sep;9(9):103689. doi: 10.1016/j.esmoop.2024.103689. Epub 2024 Sep 11. ESMO Open. 2024. PMID: 39265219 Free PMC article.
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
Collinson F, Royle KL, Swain J, Ralph C, Maraveyas A, Eisen T, Nathan P, Jones R, Meads D, Min Wah T, Martin A, Bestall J, Kelly-Morland C, Linsley C, Oughton J, Chan K, Theodoulou E, Arias-Pinilla G, Kwan A, Daverede L, Handforth C, Trainor S, Salawu A, McCabe C, Goh V, Buckley D, Hewison J, Gregory W, Selby P, Brown J, Brown J; all the STAR investigators. Collinson F, et al. Among authors: salawu a. Health Technol Assess. 2024 Aug;28(45):1-171. doi: 10.3310/JWTR4127. Health Technol Assess. 2024. PMID: 39250424 Free PMC article. Clinical Trial.
89 results